Compositions and methods related to anti-CD19 antibody drug conjugates

Abstract The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD 19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal ant...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Sung Min, CHAE, Jeiwook, FISCHER, Nicolas, KIM, Hyoung Rae, OH, Yeong Soo, PARK, Yun Hee, DEEHAN, Maureen, OH, Ji Hye, SONG, Ho Young, RYU, Hyun Min, KIM, Yong Zu
Format Patent
LanguageEnglish
Published 11.05.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Abstract The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD 19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD 19, as well as methods of making and using tltese anti-CD 19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
Bibliography:Application Number: AU20230202448